Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bee Venom Suppresses EGF-Induced Epithelial-Mesenchymal Transition and Tumor Invasion in Lung Cancer Cells.
|
31786944 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Family with sequence similarity 83 member A (FAM83A) can promote tumor cell proliferation and facilitate epidermal growth factor tyrosine kinase inhibitor resistance in some malignant tumors, but its role in lung cancer has not been directly explored.
|
31594212 |
2019 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer is one of the leading cause of cancer death worldwide, the most common histological type of lung cancer is non-small cell lung cancer (NSCLC), whose occurrence and development is closely related to the mutation and amplification of epidermal growth factor receptors (EGFR).
|
30868964 |
2019 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with advanced or metastatic forms of lung cancer with an activating mutation in <i>epidermal growth factor receptor</i> (<i>EGFR</i>) are given tyrosine kinase inhibitors (TKIs) targeted therapies that are more efficient than chemotherapy.
|
30775029 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast to normal epithelial cells, EGF stimulation of lung cancer cell lines that lack DUOX1 promotes EGF-induced EGFR internalization and nuclear localization, associated with induction of EGFR-regulated genes and related tumorigenic outcomes.
|
30890751 |
2019 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the risk of lung cancer associated with EGF+61 A>G SNP in the Brazilian population.
|
30783937 |
2019 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung cancer patients.
|
31132309 |
2019 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, SP-D has been shown to suppress lung cancer progression <i>via</i> interference with the epidermal growth factor signaling.
|
30127783 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistent with the role of NEDD4, cathepsin B is pivotal for both basal and the EGF-stimulated lung cancer cell migration.
|
29455656 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGFR ligands (e.g., EGF and TGFA) have been shown to be clinically associated with poor survival in lung cancer.
|
29662194 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF induced various rates of EGFR endocytic degradation in lung cancer cells.
|
29976202 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We searched for novel mechanistic biomarkers of AAH in an EGF transgenic disease model of lung cancer.
|
29960043 |
2018 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pretreatment of A549 lung cancer and JygMC(A) triple-negative breast cancer cells with rhTIMP-2-6XHis in low-nanomolar amounts inhibited EGF-induced proliferation to basal (unstimulated) levels.
|
29140689 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum concentrations of Epidermal Growth Factor, sCD26, Calprotectin, Matrix Metalloproteinases -1, -7, -9, CEA and CYFRA 21.1 were determined in 140 patients with respiratory symptoms (lung cancer and controls with/without benign pathology).
|
28117344 |
2017 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As both lesions were resected, were of the same histologic subtype and presented the same immunohistochemistry profile; we decided to perform mutational analysis of the epidermal growth factor (EGFR) gene to differentiate between recurrence and second primary lung cancer.
|
26663872 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we assessed the diagnostic value of epidermal growth factor (egf) and cancer antigens 125 (ca125) and 15-3 (ca15-3) in bronchoalveolar lavage fluid (balf) of lung cancer from 79 enrolled patients with suspected lung cancer.
|
28680284 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, CITED4 functions as a molecular switch in HB-EGF-induced growth control, and HB-EGF provides a novel therapeutic target for lung cancer intervention.
|
28092674 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer.
|
29238696 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
EGF could trigger resistance to RET inhibition in CCDC6-RET lung cancer cells, and endothelial cells may confer resistance to RET inhibitors by EGF.
|
27873490 |
2017 |
Malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
|
28351036 |
2017 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with Icotinib.
|
27807951 |
2016 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expert consensus guidelines have defined minimum requirements for routine testing and identification of classical epidermal growth factor (EGFR) mutations (ie, exon 19 deletions and exon 21 L858R substitution) and anaplastic lymphoma kinase (ALK) rearrangements in advanced non-small-cell lung cancers of adenocarcinoma histology, with the intent of permitting use of these predictive biomarkers to select patients who will derive maximal benefit from approved oral tyrosine kinase inhibitors (TKIs) directed against EGFR and ALK, respectively.
|
27381270 |
2016 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To establish and develop a reliable and simple Real-time PCR assay with high resolution melting (Real-time PCR-HRM) method for detection epidermal growth factor (EGFR) and BIM mutation of lung cancer and looking for effective targeted drugs to control lung cancer.
|
27424979 |
2016 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Smoking patients with lung cancer with EBs were significantly younger (63.6 versus 67.7 years, p = 0.0179) and had tumors with a lower frequency of epidermal growth factor gene (EGFR) mutations (3.8% versus 24.2%, p = 0.0184) compared with those without EBs.
|
27164304 |
2016 |
Malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
|
26572169 |
2015 |